表紙
市場調查報告書

全球類鴉片物質誘發性便秘市場(2020年∼2024年)

Global Opioid-Induced Constipation Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 967805
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球類鴉片物質誘發性便秘市場(2020年∼2024年) Global Opioid-Induced Constipation Market 2020-2024
出版日期: 2020年09月22日內容資訊: 英文 120 Pages
簡介

全球類鴉片物質誘發性便秘的市場規模,在2020年∼2024年間預測將成長到33億9000萬美元,在預測期間內預計將以21%的年複合成長率推移。市場成長的主要因素有全球類鴉片物質處方的增加,老年人口的增加,及類鴉片物質為主的醫藥品給付的可利用性。

本報告提供類鴉片物質誘發性便秘市場調查,提供市場概要,市場成長要素及阻礙因素分析,各給藥途徑·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模2019
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各給藥途徑市場區隔

  • 市場區隔
  • 各給藥途徑比較
  • 口服-市場規模與預測(2019年-2024年)
  • 非口服-市場規模與預測(2019年-2024年)
  • 各給藥途徑市場機會

各級藥品市場區隔

  • 外周作用類阿片受體拮抗劑
  • 局部作用氯離子通道活化劑
  • 其他

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美-市場規模與預測(2019年-2024年)
  • 歐洲-市場規模與預測(2019年-2024年)
  • 亞洲-市場規模與預測(2019年-2024年)
  • 其他地區-市場規模與預測(2019年-2024年)
  • 主要的主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Ironwood Pharmaceuticals Inc.
  • Mallinckrodt Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.

附錄

目錄
Product Code: IRTNTR45210

Technavio has been monitoring the opioid-induced constipation market and it is poised to grow by $ 3.39 bn during 2020-2024, progressing at a CAGR of 21% during the forecast period. Our reports on the opioid-induced constipation market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increase in opioid prescriptions globally, a rise in the geriatric population, and the availability of reimbursements for opioid-based medications. In addition, an increase in opioid prescriptions globally is anticipated to boost the growth of the market as well.

The opioid-induced constipation market analysis includes the route of administration segment, class of drug, and geographical landscapes.

Technavio's ‘opioid-induced constipation market ’ is segmented as below:

By Route of Administration

  • Oral
  • Parenteral

By Class of Drugs

  • Peripherally acting mu-opioid receptor antagonists
  • Locally acting chloride channel activator
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rise in the incidence of chronic diseases such as arthritis, back pain, and migraine as one of the prime reasons driving the opioid-induced constipation market growth during the next few years. Also, market dominance by opioid receptor antagonists and the introduction of separate diagnostic guidelines for idiopathic or functional constipation and opioid-induced constipation will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the opioid-induced constipation market covers the following areas:

  • Opioid-induced constipation market sizing
  • Opioid-induced constipation market forecast
  • Opioid-induced constipation market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading opioid-induced constipation market vendors that include AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Also, the opioid-induced constipation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by route of administration

  • Market segments
  • Comparison by route of administration
  • Oral - Market size and forecast 2019-2024
  • Parenteral - Market size and forecast 2019-2024
  • Market opportunity by route of administration

Market Segmentation by class of drugs

  • Peripherally acting mu-opioid receptor antagonists
  • Locally acting chloride channel activator
  • Other drugs

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Ironwood Pharmaceuticals Inc.
  • Mallinckrodt Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Key Finding 9
  • 9: Parent market
  • 10: Market characteristics
  • 11: Offerings of vendors included in the market definition
  • 12: Market segments
  • 13: Global - Market size and forecast 2019 - 2024 ($ million)
  • 14: Global market: Year-over-year growth 2019 - 2024 (%)
  • 15: Five forces analysis 2019 & 2024
  • 16: Bargaining power of buyers
  • 17: Bargaining power of suppliers
  • 18: Threat of new entrants
  • 19: Threat of substitutes
  • 20: Threat of rivalry
  • 21: Market condition - Five forces 2019
  • 22: Other1 - Market share 2019-2024 (%)
  • 23: Comparison by Other1
  • 24: Oral - Market size and forecast 2019-2024 ($ million)
  • 25: Oral - Year-over-year growth 2019-2024 (%)
  • 26: Parenteral - Market size and forecast 2019-2024 ($ million)
  • 27: Parenteral - Year-over-year growth 2019-2024 (%)
  • 28: Market opportunity by Other1
  • 29: Other2 - Market share 2019-2024 (%)
  • 30: Comparison by Other2
  • 31: Peripherally acting mu-opioid receptor antagonists - Market size and forecast 2019-2024 ($ million)
  • 32: Peripherally acting mu-opioid receptor antagonists - Year-over-year growth 2019-2024 (%)
  • 33: Locally acting chloride channel activator - Market size and forecast 2019-2024 ($ million)
  • 34: Locally acting chloride channel activator - Year-over-year growth 2019-2024 (%)
  • 35: Others - Market size and forecast 2019-2024 ($ million)
  • 36: Others - Year-over-year growth 2019-2024 (%)
  • 37: Market opportunity by Other2
  • 38: Customer landscape
  • 39: Market share by geography 2019-2024 (%)
  • 40: Geographic comparison
  • 41: North America - Market size and forecast 2019-2024 ($ million)
  • 42: North America - Year-over-year growth 2019-2024 (%)
  • 43: Europe - Market size and forecast 2019-2024 ($ million)
  • 44: Europe - Year-over-year growth 2019-2024 (%)
  • 45: Asia - Market size and forecast 2019-2024 ($ million)
  • 46: Asia - Year-over-year growth 2019-2024 (%)
  • 47: ROW - Market size and forecast 2019-2024 ($ million)
  • 48: ROW - Year-over-year growth 2019-2024 (%)
  • 49: Key leading countries
  • 50: Market opportunity by geography ($ million)
  • 51: Impact of drivers and challenges
  • 52: Vendor landscape
  • 53: Landscape disruption
  • 54: Industry risks
  • 55: Vendors covered
  • 56: Market positioning of vendors
  • 57: AstraZeneca Plc - Overview
  • 58: AstraZeneca Plc - Product and service
  • 59: AstraZeneca Plc - Key offerings
  • 60: AstraZeneca Plc - Key customers
  • 61: AstraZeneca Plc - Segment focus
  • 62: Bausch Health Companies Inc. - Overview
  • 63: Bausch Health Companies Inc. - Business segments
  • 64: Bausch Health Companies Inc. - Key offerings
  • 65: Bausch Health Companies Inc. - Key customers
  • 66: Bausch Health Companies Inc. - Segment focus
  • 67: Daiichi Sankyo Co. Ltd. - Overview
  • 68: Daiichi Sankyo Co. Ltd. - Business segments
  • 69: Daiichi Sankyo Co. Ltd. - Key offerings
  • 70: Daiichi Sankyo Co. Ltd. - Key customers
  • 71: Daiichi Sankyo Co. Ltd. - Segment focus
  • 72: Ironwood Pharmaceuticals Inc. - Overview
  • 73: Ironwood Pharmaceuticals Inc. - Business segments
  • 74: Ironwood Pharmaceuticals Inc. - Key offerings
  • 75: Ironwood Pharmaceuticals Inc. - Key customers
  • 76: Ironwood Pharmaceuticals Inc. - Segment focus
  • 77: Mallinckrodt Plc - Overview
  • 78: Mallinckrodt Plc - Business segments
  • 79: Mallinckrodt Plc - Key offerings
  • 80: Mallinckrodt Plc - Key customers
  • 81: Mallinckrodt Plc - Segment focus
  • 82: Merck & Co. Inc. - Overview
  • 83: Merck & Co. Inc. - Business segments
  • 84: Merck & Co. Inc. - Key offerings
  • 85: Merck & Co. Inc. - Key customers
  • 86: Merck & Co. Inc. - Segment focus
  • 87: Novartis AG - Overview
  • 88: Novartis AG - Business segments
  • 89: Novartis AG - Key offerings
  • 90: Novartis AG - Key customers
  • 91: Novartis AG - Segment focus
  • 92: Pfizer Inc. - Overview
  • 93: Pfizer Inc. - Business segments
  • 94: Pfizer Inc. - Key offerings
  • 95: Pfizer Inc. - Key customers
  • 96: Pfizer Inc. - Segment focus
  • 97: SHIONOGI Co. Ltd. - Overview
  • 98: SHIONOGI Co. Ltd. - Business segments
  • 99: SHIONOGI Co. Ltd. - Key offerings
  • 100: SHIONOGI Co. Ltd. - Key customers
  • 101: SHIONOGI Co. Ltd. - Segment focus
  • 102: Takeda Pharmaceutical Co. Ltd. - Overview
  • 103: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 104: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 105: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 106: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 107: Currency conversion rates for US$
  • 108: Research Methodology
  • 109: Validation techniques employed for market sizing
  • 110: Information sources
  • 111: List of abbreviations